NCT02858908View on ClinicalTrials.gov

Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy

PHASE2CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

July 20, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions

Myotonic Dystrophy 1

Interventions

DRUG

Tideglusib

Tideglusib for oral suspension,

Trial Locations (1)

NE1 4LP

Newcastle-upon-Tyne Hospitals NHS Trust, Newcastle upon Tyne

Sponsors

Lead Sponsor

AMO Pharma Limited

All Listed Sponsors

lead

AMO Pharma Limited

INDUSTRY

NCT02858908 - Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy | Biotech Hunter | Biotech Hunter